Patient guide · Reviewed June 2026
Compounded GLP-1 Medications in Australia — What Changed and What to Do Now
If you've been using a compounded version of a GLP-1 medication — a pharmacy-prepared semaglutide or tirzepatide product rather than a TGA-approved branded pen like Ozempic, Wegovy or Mounjaro — the rules around this changed significantly in late 2024. Here's what happened and what it means for you now.
Published 2026-06-01 · Clinically reviewed 2026-06-03
Patient guide · Reviewed June 2026
The ban: October 1, 2024
As of 1 October 2024, the compounding exemption that previously allowed Australian pharmacies to prepare GLP-1 receptor agonist medications was removed. Before…
As of 1 October 2024, the compounding exemption that previously allowed Australian pharmacies to prepare GLP-1 receptor agonist medications was removed. Before this date, community pharmacists could legally prepare customised versions of these medications under an extemporaneous compounding exemption — without needing the same Good Manufacturing Practice (GMP) licensing required of standard commercial drug manufacturing. This exemption existed for legitimate clinical reasons (allowing tailored doses or formulations where needed), but it was also the route used by a number of high-volume digital health platforms to supply lower-cost "copycat" semaglutide and tirzepatide products during a period of significant commercial shortages of the branded medications.
Since the ban, pharmacies are strictly prohibited from producing replica versions of Ozempic, Wegovy, Mounjaro or any other GLP-1 receptor agonist. This removed the entire compounded-GLP-1 business model in a single regulatory action.
What this means if you're still using a compounded product
If you're currently using a compounded semaglutide or tirzepatide product, it's worth understanding exactly where that leaves you:
If you're using existing stock obtained before the ban, you're not doing anything illegal simply by continuing to use medication you already legitimately purchased — but you should be aware that this stock cannot be renewed or re-supplied through the same channel now that the exemption has been removed.
If you're being offered a "compounded" GLP-1 product after October 2024, this indicates the supplier is operating outside the current regulatory framework. Any pharmacy or clinic still offering to compound these medications post-ban is not complying with TGA requirements, and sourcing medication this way carries genuine risks — compounded products lacked standardised bioavailability controls even before the ban, meaning dosing consistency between batches was never guaranteed in the way it is for TGA-approved commercial products.
Patient guide · Reviewed June 2026
What you should do
The clear, current advice is to transition to a TGA-approved, regulated medication via your GP as soon as practical. This means moving to a branded product —…
The clear, current advice is to transition to a TGA-approved, regulated medication via your GP as soon as practical. This means moving to a branded product — Ozempic, Wegovy, or Mounjaro — prescribed and dispensed through standard, compliant channels.
A few practical points worth knowing about this transition:
Re-titration is important, not optional. Because compounded products lacked standardised bioavailability controls, you can't assume your previous compounded dose translates directly to an equivalent commercial dose. The safe approach is to restart titration from the lowest commercial starting dose (typically 0.25 mg for semaglutide-based products, or the equivalent lowest dose for tirzepatide), rather than jumping straight to whatever dose you believe you were previously on. This reduces the risk of severe gastrointestinal side effects or other adverse effects that can occur if your body receives a higher or less predictable dose than it's adjusted to.
Expect a different price point. Commercial branded medications are priced differently to compounded products, and this is often a significant factor for patients who chose compounding specifically for cost reasons. It's worth having a direct conversation with your GP about the realistic ongoing cost before you commit to a switch, so there are no surprises.
Full annual cost of GLP-1 therapy →
Tell your GP the full history. If you've been using a compounded product, say so plainly when you see your doctor — this affects how they assess your starting dose, your tolerance history, and what monitoring might be appropriate, particularly if you experienced side effects on the compounded version that may have been dose-related rather than drug-related.
Why this matters beyond just compliance
This isn't only a legal or administrative issue. The October 2024 changes were driven partly by concerns about consistency and safety in a product category where dosing precision matters considerably — GLP-1 medications are titrated carefully specifically because gastrointestinal tolerability and effectiveness are dose-dependent, and inconsistent compounded formulations made that titration process less predictable and less safe.
If you're currently on a compounded product and haven't yet discussed a transition with your GP, this is worth raising at your next appointment rather than waiting for a supply issue to force the conversation.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Is compounded semaglutide legal in Australia?
No. Since 1 October 2024, pharmacies are prohibited from compounding replica GLP-1 receptor agonist medications including semaglutide and tirzepatide.
Can I still use compounded GLP-1 I bought before the ban?
Using legitimately purchased stock is not illegal, but it cannot be renewed through compounding channels. Transition to TGA-approved medication via your GP.
Do I need to restart dosing when switching from compounded to branded GLP-1?
Yes. Restart titration from the lowest commercial starting dose — compounded bioavailability was inconsistent and doses don't translate directly.
Why did Australia ban compounded GLP-1?
The TGA removed the compounding exemption due to safety and consistency concerns, and because the exemption was being used for high-volume copycat products outside its intended purpose.
Therapeutic Goods Administration (TGA), compounding exemption changes for GLP-1 receptor agonists, effective 1 October 2024; reporting on telehealth weight-loss clinic operational transitions following the compounding ban.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.